Abattis Announces an Independent Valuation on Green Nature Health Care Products (PR)

0 Responses Abattis News

VANCOUVER, BC / ACCESSWIRE / January 16, 2017 Abattis Bioceuticals Corp. (ATTBF) (CNSX:ATT) (the “Company” or “Abattis”) provides an update to its shareholders. Abattis Bioceuticals Corp. has begun an independent valuation on Green Nature Health Care Products Inc. after the company posted strong performance within their existing and upcoming product catalogue in both Q3 and […]

Abattis Bioceuticals (ATTBF) Northern Vine Labs and the New Canadian Rules (CFN Media)

0 Responses Abattis News | Health Canada | Northern Vine

SEATTLE, WA / Marketwired / Jan 5, 2017 CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Abattis Bioceuticals Corp.’s ( OTCQB : ATTBF ) ( CSE : ATT ) Northern Vine Labs subsidiary and the effect newly proposed rules in Canada […]

Abattis Provides Corporate Update (PR: 12/16/16)

0 Responses Abattis News | Northern Vine

VANCOUVER, BC / December 16, 2016 Abattis Bioceuticals Corp. (ATTBF) (CNSX:ATT) (the “Company” or “Abattis”) provides an update to its shareholder. CEO Rene David provides an update to shareholders after reviewing the latest report from the Canadian Cannabis Task Force on Legalization and Regulation. “After having a chance to review the report, we are even […]

Abattis (ATTBF) Targets Emerging Markets with Nutraceutical Business (CFN Media)

0 Responses Abattis News

SEATTLE, WA / Marketwired / Nov 28, 2016 CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Abattis Bioceuticals Corp.’s ( OTCQB : ATTBF ) ( CSE : ATT ) recent expansion of distribution lines in Asia and how those efforts complement […]

Abattis Announces the Appointment of Dr. Shuang Xie as a Director and Provides Progress Report on Initiatives in China (PR)

0 Responses Abattis News

VANCOUVER, BC / ACCESSWIRE / November 14, 2016 Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”), is pleased to announce the appointment of Dr. Shuang Xie to the Board of Directors. Dr. Xie recently joined Abattis as the Chief Technology Advisor and continues in that capacity. Abattis is also pleased provide an update on […]

Abattis Announces Renewal of Health Canada Licence (PR)

0 Responses Abattis News | Health Canada

VANCOUVER, BC / ACCESSWIRE / November 7, 2016 Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”), announces the renewal of the Health Canada Licence for the Northern Vine Canada Inc. testing lab. Health Canada has confirmed the renewal of the Langley, BC facility’s controlled substances testing licence. The Company has fulfilled Health Canada’s rigorous […]

Abattis Announces the Appointment of New Independent Director (PR)

0 Responses Abattis News | Northern Vine

VANCOUVER, BC / ACCESSWIRE / November 2, 2016 Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”), announces the appointment of Dr. William Panenka to the Board of Directors. Dr. Panenka received his M.D. and M.Sc. from the University of Calgary in Canada. His M.Sc was basic science-focused utilizing Western Blotting, PCR, in-situ hybridization and […]

Abattis’ Federally Licensed Lab and the Crucial Role It Plays (CFN Media)

0 Responses Abattis News | Northern Vine

SEATTLE, WA / Marketwired / Nov 2, 2016 CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Abattis Bioceuticals ( OTCQB : ATTBF ) ( CSE : ATT ). The company recently announced the receipt of a Controlled Substance License from Health […]

Abattis Executes Memorandum of Agreement to Acquire 100% of Experion Biotechnologies Inc. (PR)

0 Responses Abattis News | Experion

VANCOUVER, BC / ACCESSWIRE / October 24, 2016 Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”), announces that Abattis and Northern Vine have entered into a Binding Memorandum of Agreement with Experion Biotechnologies to acquire up to 100% of Experion Biotechnologies Inc. Abattis Bioceuticals Corp., and its subsidiary Northern Vine Canada Inc., expect to […]

Abattis (ATTBF): A Leader in Canada’s Cannabis Testing Industry (CFN Media)

0 Responses Abattis News | Health Canada

SEATTLE, WA / Marketwired / Oct 18, 2016 CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Canada’s new cannabis testing regulations and why Abattis Bioceuticals’ ( OTCQB : ATTBF ) Northern Vine Labs is well positioned in this burgeoning market. In […]

Abattis Bioceuticals Corp: Experion Biotechnologies Prepares for Construction (PR)

0 Responses Abattis News | Experion | Northern Vine

VANCOUVER, BC / ACCESSWIRE / October 17, 2016 Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”), announces commencement of construction for the Experion secure, production facility. Experion Biotechnologies Inc. is pleased to announce that it has begun the construction process and prepares to break ground for the six-month build-out for its 8,000 square foot, […]

Abattis Signs MOU with Global Damon Pharma of South Korea (PR)

0 Responses Abattis News

VANCOUVER, BC / ACCESSWIRE / October 5, 2016 Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”) is pleased to announce that it has entered into a Memorandum of Understanding with Global Damon Pharma (“GDP”) of South Korea, to distribute and sell Abattis’ proprietary PhytoNOS™ and Sassy™ Tonics in modified formulations. GDP will engage in […]

Update: New Science Advisor and Comptroller Appointment to Abattis (PR)

0 Responses Abattis News

VANCOUVER, BC / ACCESSWIRE / September 27, 2016 Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”) is pleased to announce the appointment of Dr. Shuang Xie as its newest Science and Technology Advisor. Dr. Xie graduated from Zhejiang University in 1987 and Queen’s University in 1993. Dr. Xie has been widely published and holds […]